Related Experiment Videos
Recurrent allograft disease: viral hepatitis
1Hospital Universitario La FE, Servicio de Gastroenterología y Hepatología, Valencia, Spain. mbhaym@teleline.es
Acta Gastro-Enterologica Belgica
|November 5, 2005
Summary
Recurrent hepatitis C after liver transplantation (LT) remains a significant challenge due to the lack of effective prevention strategies. This leads to rapid graft fibrosis and reduced patient survival, unlike hepatitis B which has successful preventative measures.
Area of Science:
- Hepatology and Transplant Surgery
- Viral Hepatitis Research
- Immunology and Infectious Diseases
Background:
- Viral hepatitis is the primary indication for liver transplantation (LT).
- Preventing allograft reinfection is crucial for post-transplantation outcomes.
- Hepatitis B recurrence is effectively managed, but hepatitis C recurrence poses a growing problem.
Purpose of the Study:
- To highlight the challenges in preventing recurrent hepatitis C post-liver transplantation.
- To discuss the limitations of current prophylactic and therapeutic strategies for hepatitis C.
- To underscore the impact of recurrent hepatitis C on graft and patient survival.
Main Methods:
- Review of current literature on viral hepatitis recurrence after LT.
- Analysis of outcomes in patients with hepatitis B versus hepatitis C recurrence.
- Evaluation of existing antiviral therapies and their toxicities.
Main Results:
- Hepatitis B recurrence is effectively prevented with immunoglobulins and antivirals.
- Hepatitis C recurrence is nearly invariable due to lack of effective prophylaxis.
- Recurrent hepatitis C leads to rapid allograft fibrosis and end-stage liver disease.
Conclusions:
- There is an urgent need for effective prophylactic therapies against recurrent hepatitis C.
- Current treatments for recurrent hepatitis C have significant toxicities limiting efficacy.
- Recurrent hepatitis C significantly decreases graft survival, increases re-transplantation rates, and reduces patient survival.